WO2024052120A1 - Functional food - Google Patents
Functional food Download PDFInfo
- Publication number
- WO2024052120A1 WO2024052120A1 PCT/EP2023/073045 EP2023073045W WO2024052120A1 WO 2024052120 A1 WO2024052120 A1 WO 2024052120A1 EP 2023073045 W EP2023073045 W EP 2023073045W WO 2024052120 A1 WO2024052120 A1 WO 2024052120A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carnosine
- functional food
- extract
- food composition
- salacia reticulata
- Prior art date
Links
- 235000013376 functional food Nutrition 0.000 title claims abstract description 37
- 108010087806 Carnosine Proteins 0.000 claims abstract description 83
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 83
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 83
- 229940044199 carnosine Drugs 0.000 claims abstract description 83
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 82
- 239000000284 extract Substances 0.000 claims abstract description 48
- 241000647991 Salacia reticulata Species 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 230000036541 health Effects 0.000 claims abstract description 8
- 230000036642 wellbeing Effects 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims description 24
- 235000009508 confectionery Nutrition 0.000 claims description 14
- 206010012601 diabetes mellitus Diseases 0.000 claims description 13
- 235000013618 yogurt Nutrition 0.000 claims description 11
- 208000008589 Obesity Diseases 0.000 claims description 8
- 235000015243 ice cream Nutrition 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 235000011888 snacks Nutrition 0.000 claims description 7
- 235000013570 smoothie Nutrition 0.000 claims description 4
- 235000012970 cakes Nutrition 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 235000012182 cereal bars Nutrition 0.000 claims description 2
- 235000014510 cooky Nutrition 0.000 claims description 2
- 235000008410 fruit bars Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 235000021067 refined food Nutrition 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 235000017709 saponins Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 241000196324 Embryophyta Species 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 230000032683 aging Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 12
- 230000036252 glycation Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 235000013399 edible fruits Nutrition 0.000 description 9
- 239000000419 plant extract Substances 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 7
- 208000002177 Cataract Diseases 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 241000545263 Salacia <hydroid> Species 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 230000003712 anti-aging effect Effects 0.000 description 5
- 235000013365 dairy product Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- -1 superoxide anions Chemical class 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 235000005979 Citrus limon Nutrition 0.000 description 4
- 244000131522 Citrus pyriformis Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 235000021028 berry Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013410 fast food Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 description 4
- 235000015205 orange juice Nutrition 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000009758 senescence Effects 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 244000075850 Avena orientalis Species 0.000 description 3
- 235000007319 Avena orientalis Nutrition 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 235000015190 carrot juice Nutrition 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000020235 chia seed Nutrition 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 235000019674 grape juice Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000003716 rejuvenation Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 2
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 2
- 244000087020 Salacia prinoides Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000003403 autonomic nervous system Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000011869 dried fruits Nutrition 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 108091005996 glycated proteins Proteins 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940043357 mangiferin Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- JTBGJQZJEYVBJZ-YLXTXNMFSA-N triptotriterpenic acid A Chemical compound C([C@H]1C2=CC[C@H]34)[C@](C)(C(O)=O)C[C@H](O)[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C JTBGJQZJEYVBJZ-YLXTXNMFSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 240000004246 Agave americana Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 240000006162 Chenopodium quinoa Species 0.000 description 1
- 208000037088 Chromosome Breakage Diseases 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000266331 Eugenia Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100026535 Fibronectin type III domain-containing protein 5 Human genes 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 101800001026 Irisin Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000134253 Lanka Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- SOWRVDSZMRPKRG-YRPOCYRVSA-N S(=O)(=O)(O[C@@H](CO)[C@@H](C[S@+]1[C@@H]([C@H]([C@@H](C1)O)O)CO)O)[O-] Chemical compound S(=O)(=O)(O[C@@H](CO)[C@@H](C[S@+]1[C@@H]([C@H]([C@@H](C1)O)O)CO)O)[O-] SOWRVDSZMRPKRG-YRPOCYRVSA-N 0.000 description 1
- 241000051611 Salacia oblonga Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000002448 anti-glycating effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002012 ayurvedic medicine Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 1
- 235000021019 cranberries Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 235000013572 fruit purees Nutrition 0.000 description 1
- 235000020351 fruit smoothie Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940029982 garlic powder Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 235000014168 granola/muesli bars Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- LNQCUTNLHUQZLR-OZJWLQQPSA-N iridin Chemical compound OC1=C(OC)C(OC)=CC(C=2C(C3=C(O)C(OC)=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC=2)=O)=C1 LNQCUTNLHUQZLR-OZJWLQQPSA-N 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HHRZAEJMHSGZNP-UHFFFAOYSA-N mebanazine Chemical compound NNC(C)C1=CC=CC=C1 HHRZAEJMHSGZNP-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 210000000557 podocyte Anatomy 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 235000013606 potato chips Nutrition 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000019675 red grape juice Nutrition 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000008943 replicative senescence Effects 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- JTBGJQZJEYVBJZ-UHFFFAOYSA-N triptocallic acid D Natural products C12CC=C3C4CC(C)(C(O)=O)CC(O)C4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C JTBGJQZJEYVBJZ-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
- H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
- H02J7/0069—Charging or discharging for charge maintenance, battery initiation or rejuvenation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R31/00—Arrangements for testing electric properties; Arrangements for locating electric faults; Arrangements for electrical testing characterised by what is being tested not provided for elsewhere
- G01R31/36—Arrangements for testing, measuring or monitoring the electrical condition of accumulators or electric batteries, e.g. capacity or state of charge [SoC]
- G01R31/367—Software therefor, e.g. for battery testing using modelling or look-up tables
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
- H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
- H02J7/007—Regulation of charging or discharging current or voltage
- H02J7/00712—Regulation of charging or discharging current or voltage the cycle being controlled or terminated in response to electric parameters
- H02J7/00714—Regulation of charging or discharging current or voltage the cycle being controlled or terminated in response to electric parameters in response to battery charging or discharging current
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
- H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
- H02J7/007—Regulation of charging or discharging current or voltage
- H02J7/00712—Regulation of charging or discharging current or voltage the cycle being controlled or terminated in response to electric parameters
- H02J7/007182—Regulation of charging or discharging current or voltage the cycle being controlled or terminated in response to electric parameters in response to battery voltage
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
- H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
- H02J7/007—Regulation of charging or discharging current or voltage
- H02J7/00712—Regulation of charging or discharging current or voltage the cycle being controlled or terminated in response to electric parameters
- H02J7/007182—Regulation of charging or discharging current or voltage the cycle being controlled or terminated in response to electric parameters in response to battery voltage
- H02J7/007186—Regulation of charging or discharging current or voltage the cycle being controlled or terminated in response to electric parameters in response to battery voltage obtained with the battery disconnected from the charge or discharge circuit
Definitions
- the present invention relates to a functional food for improving human nutrition and which contributes to human health in a sustainable manner.
- L-carnosine (0-alanyl-L-histidine, hereinafter referred to as carnosine) is a dipeptide discovered from the skeletal muscles in 1900's, and is present in high concentrations (1-20 mM) in the skeletal muscles of various vertebrates.
- Carnosine is a water-soluble antioxidant in the living body. Carnosine serves to stabilize the cell membrane by preventing the peroxidization of lipids in the membrane or by eliminating superoxide anions.
- Carnosine is known not only as an antioxidant but as a neurotransmitter, an enzyme activity modulator, and a chelating agent for metal ions.
- EP1285654A discloses a composition comprising carnosine, in which said composition comprises carnosine so that the amount of carnosine per ingestion is 0.7 pg/kg to 0.09 mg/kg, and which may take the form of a tablet, a capsule, powders, granules, a drink, bread, biscuit, cake and the like.
- the composition preferably has an effect of controlling the autonomic nervous system, and more specifically it has an effect of preventing, improving or alleviating disturbances in the autonomic nervous system and disease conditions resulting therefrom.
- Herbal remedies are also used as a natural variant of food supplements in the form of extracts or crushed product.
- Salacia species are used for the treatment or alleviation of diabetes and obesity.
- Salacia is known to improve intestinal flora and is said to be effective against rheumatism, gonorrhea and skin diseases.
- W02008/142702A describes a synergistic bioactive Ayurvedic/functional food composition for the treatment of diabetes and related disorders.
- the composition comprises extracts of at least two plants selected from a group consisting of Eugenia, Cinnamomum and Salacia obionga.
- Medagama et al Medagama Nutrition Journal 2015, 14(21 ):1 -8) provide an overview of the role of Salacia reticulata in the treatment of diabetes and obesity.
- Ofner et al (Cell Cycle 2013; 12:2, 346-352) describe complementary treatment of obesity and overweight with Salacia reticulata and vitamin D.
- Narda et al (Skin Pharmacol. Physiol. 2018, 31 :324-331) describe a new face cream containing carnosine that inhibits the formation of AGEs in human skin.
- the present invention is based on the task of functionalizing a conventional foodstuff by adding an extract of the plant Salacia reticulata / such a way that by consuming this foodstuff the extract can develop its comprehensive effect.
- the present invention relates to a conventional food product which has been functionalized by adding an extract of the plant Salacia reticulata. By consuming this functionalized foodstuff, the extract of the plant Salacia reticulata contained in the foodstuff can develop its comprehensive effect.
- Nutrition also has a major influence on skin aging.
- Skin aging is a complex, chronic process that takes place over several years and involves the interaction of external and intrinsic factors. Mechanisms such as oxidative stress caused by free radicals, inflammatory processes, cellular senescence and epigenetic changes are not mutually exclusive mechanisms that are part of skin aging.
- Glycosylation the non-enzymatic reaction between proteins and sugars that leads to the formation and subsequent accumulation of advanced glycosylation end products (AGEs)
- AGEs have been linked to microvascular and macrovascular complications in diabetes.
- AGEs have been found to be associated with extracellular matrix proteins such as collagen, vimentin, and elastin.
- AGE-modified collagen and elastin have been reported to have altered biomechanical properties that lead to loss of elasticity and increased stiffness, and thus to changes that promote the appearance of wrinkles.
- l-carnosine has been associated with protection against glycosylation when taken orally.
- Carnosine is a highly potent, multifunctional anti-aging protein that occurs 100% naturally in human long-lived cells such as nerve and muscle cells and decreases with age. Carnosine levels decline with age. Muscle levels decline 63% from age 10 to age 70, which may account for the normal age-related decline in muscle mass and function (Stuerenburg HJ et aL, Arch Gerontol Geriatr. 1999. 29: 107-113). Carnosine fights such age-inducing processes as oxidation, glycation, protein cross-linking, mitochondrial dysfunction, telomere shortening, 64 and transition metal accumulation. Therefore carnosine is may delay aging of subjects.
- Carnosine was discovered at the beginning of the 20th century. Taken as a dietary supplement, carnosine could promote muscle growth and could reduce muscle damage caused by intensive training. [0023] Carnosine restores normal cell cycle control. It keeps human proteins healthy and intact and ensures their timely renewal. Human cells have only a limited ability to divide over the course of life. Human fibroblasts (skin cells from which taut collagen fibers develop) divide 60-80 times when they are young and only 10-20 times when they get older, and may take on strikingly abnormal sizes and shapes in cell cultures (Sadowska-Bartosz I. and Bartosz G, Oxid Med Cell Longev. 2020 Sep 23;2020:6423783).
- Glycation describes the binding of a protein molecule to glucose, whereupon advanced glycation end products (AGEs) are formed after several steps (Burcham PC, and Kuhan YT. Arch Biochem Biophys, 1997, 340(2):331-7).
- AGEs advanced glycation end products
- Carnosine may delay age induced processes such as glycation.
- Carnosine is considered as the most effective glycation fighter. Glycation alters protein structure and decreases biological activity. Glycated proteins, which accumulate in affected tissue, are reliable markers of disease. Carnosine, which prevents glycation, may also play a role in the disposal of glycated protein (Aldini G. et al. , Biochem Biophys Res Commun. 2002 Nov 15;298(5):699-7062002, Yeargans G.S. and Seidler N.W.
- Carnosine increases the conversion of dangerous white fat into brown fat. This can reduce overall body fat content.
- Schaalan et al. suggest that carnosine may induce browning of adipose tissue through irisin stimulation, a phenomenon that could be related to the antioxidant, anti-inflammatory, and anti-obesity effects of carnosine (Schaalan M.F. et al., J Cell Physiol . 2018 Jun;233(6):5044-5057).
- McFarland G.A. and Holliday R. have shown that a transfer of cells approaching senescence in normal medium to medium supplemented with carnosine rejuvenates the cells (McFarland
- Carnosine increased myocyte tension via calcium release from the ryanodine receptor calcium release channel in skinned myocardial fibers and increased openstate probability and dwell time of the isolated ryanodine receptor calcium release channel in lipid bilayers.
- carnosine sensitizes the contractile proteins so calcium.
- carnosine exhibits anti-glycating and antioxidant activities, both of which are implicated in neuronal and endothelial cell damage during Alzheimer's disease.
- Carnosine may therefore be a useful therapeutic agent in the treatment of neurologic diseases such as Alzheimer(Preston J.E. et aL, Neurosci Lett. 1998 Feb 13;242(2): 105-8, Aksenova MV, et aL, J Neurosci Res. 1999; 58(2):308-17, Cherny RA, et aL, J Biol Chem . 1999;274:23223-8).
- Atherosclerosis a chronic inflammatory disorder of medium and large arteries and an underlying cause of cardiovascular disease (CVD), is responsible for a third of all global deaths.
- Carnosine may represent a promising agent in the prevention and treatment of atherosclerosis (Moss J.W.E. et aL, Biochim Biophys Acta Mol Basis Dis. 2018 May; 1864(5 Pt A): 1562-1572).
- a drug that could slow or reverse AGEs accumulation would thus benefit people with a wide range of diseases and conditions. It could potentially alleviate or even cure problems as wide-ranging as the rise in blood pressure with age, the kidney, nerve and eye complications of diabetes, and several forms of heart failure.
- the therapeutic potential of carnosine has already been demonstrated in diabetics with kidney problems (Sourris K.C. et al, Am J Nephrol (2009) 30 (4): 323-335). Janssen B. et al. describe that carnosine exerts a protective effect against the adverse effects of high glucose levels on renal cells (Janssen B. et aL, Diabetes (2005) Aug;54(8):2320- 7).
- carnosine may be the most effective natural glycation inhibitor.
- Another protein change results from oxidation/oxidative stress by free radicals. Carnosine is far superior to the previous antioxidants such as vitamins C and E, or selenium. These have not been proven as effective as previously assumed. Carnosine is not only effective in prevention, but also acts actively after free radicals have been formed. The formation of dangerous secondary products that play a role in atherosclerosis, joint inflammation, cataracts, etc. and general aging may be prevented or reduced by carnosine (Schmidt AM et aL, Circ Res 1999; 84(5):489-97).
- a functional food which allows "enjoyment without regrets".
- the intake of the functional food may improve health and possible save on prescription of medicines.
- the present invention relates to a highly potent, water-soluble anti-AGE active ingredient in food for general consumption, as a so-called functional food or luxury food ("enjoyment without regrets") such as alcohol- free spirits, confectionery, snacks or fruit/vegetable products.
- the functional food may be ideal for healthy people who want to age youthfully, but also as an auxiliary food for people suffering from obesity, diabetes or other chronic diseases.
- the functional food may comprise a Salacia reticulata extract.
- the genus Salacia consists of about 120 species, such as Salacia reticulata, Salacia oblonga, Salacia chinensis or Salacia prinoides, and is widely distributed in Sri Lanka, India, China, Vietnam, Indonesia and other Asian countries.
- Salacia reticulata improves glucose metabolism, mainly by inhibiting alpha-glucosidase, thereby delaying the cleavage of poly- and oligosaccharides in the small intestine into easily absorbed monosaccharides and consequently their absorption. Extracts of Salacia reticulata thus attenuate postprandial hyperglycemia and hypersinsulinemia (Medagama AB, 2015).
- Salacia also improves insulin resistance by suppressing pancreatic lipase activity, which is a crucial enzyme in the pancreas for the digestion of dietary fat. Extracts of Salacia reticulata ihus attenuate postprandial hyperlipidemia. Further studies have shown increased secretion of adiponectin, which further improves insulin resistance (Medagama AB, 2015).
- Carnosine is a dipeptide synthesized in the body from p-alanine and L- histidine. It is found in high concentrations in the brain, muscle, and gastrointestinal tissues of humans and is present in all vertebrates. Carnosine has a number of beneficial antioxidant properties. For example, carnosine scavenges reactive oxygen species (ROS) as well as alpha-beta unsaturated aldehydes created by peroxidation of fatty acid cell membranes during oxidative stress. Carnosine can oppose glycation, and it can chelate divalent metal ions. Carnosine alleviates diabetic nephropathy by protecting podocyte and mesangial cells, and can slow down aging.
- ROS reactive oxygen species
- Carnosine can oppose glycation, and it can chelate divalent metal ions.
- Carnosine alleviates diabetic nephropathy by protecting podocyte and mesangial cells, and can slow down aging.
- amino acid beta-alanine is particularly interesting as a dietary supplement for athletes because it increases muscle carnosine, and improves effectiveness of exercise and stimulation and contraction in muscles.
- Carnosine is widely used among athletes in the form of supplements, but rarely in the population of cardiovascular or diabetic patients. Much less is known, if any, about its potential use in enriched food.
- carnosine As an anti-AGE active ingredient, carnosine increases and tightens the elasticity of the skin. Carnosine is able to significantly reduce the external signs of aging by extending the lifespan (in cell cultures up to 300%, equivalent to 413 days) and by rejuvenating old, senescent cells. As an antioxidant, it leads to slow aging due to its pronounced cell protection and thus has a cell rejuvenating effect without the risk of side effects.
- carnosine is able to prevent intramuscular hyperacidity by reducing the accumulation of lactate, regulate the energy metabolism of muscles and thus improve physical performance. This in turn has positive effects on the overall physical fitness which is reflected in higher vital energy, vitality and an improvement in the overall health of the person.
- anti-inflammatory and anti-aggregation properties expand the therapeutic range of carnosine. This therapeutic potential has already seen initial success in the treatment of type 2 diabetes mellitus, Alzheimer's disease and cardiovascular disease.
- plant extract refers to a substance obtained from plant material.
- Plant extracts may be prepared by treating any plant material with a suitable extractant to provide an extract containing at least some components of the plant material from the plant material in aqueous solution or suspension.
- the plant material treated with an extractant to provide a plant extract may be any part of or derived from a plant, for example, the bark, roots, leaves, flowers, seeds or fruits of the plant.
- plant extracts are well known to the skilled person.
- the plant extracts may be obtained by decoction, digestion, percolation, soxlethtation, maceration, or any other suitable extraction method.
- the plant components extracted from the plant material will be at least partially soluble or suspendable in an extractant, preferably an organic solvent or water.
- an extractant preferably an organic solvent or water.
- the insoluble plant material may remain in the extractant, or the insoluble plant material may be separated from the extractant.
- the insoluble plant material may be separated from the extractant by any suitable method, for example, decantation, filtration, or centrifugation.
- the insoluble plant material is separated from the extractant, and the plant extract contains no insoluble components.
- the plant extract is in aqueous solution or in a form where the extractant has been sufficiently removed to provide a dry or non-aqueous extract.
- the plant extract Salacia reticulata is obtained from the roots and/or stem bark of a plant of the genus Salacia reticulata.
- the Salacia reticulata extract is directly processed or incorporated into a food product to thereby provide a functional food.
- Other active ingredients can be added to the functional food, such as cinnamon, vitamins and the like.
- the present invention relates to food products made by combining various dairy (substitute), chocolate, sugar, dough, cereal, meat, and fish-based products, as well as fruits and vegetables.
- Functional foods may also include beverages.
- the functional foods may contain other ingredients such as flavors, sweeteners, flow regulators, and anti-caking agents.
- functional foods are selected from the group consisting of yogurts, yogurt substitutes, dips, spreads, pastes, snacks, ice cream, candies, cookies, cakes, cereal bars, fruit bars, smoothies, and the like.
- the term "snacks”, as used herein, is understood to mean food products produced as a composition of various processed and unprocessed foods/products. Such snacks can be produced by conventional processes known to the skilled person.
- the functional food according to the invention is suitable as a food of general consumption by a healthy person, or as a food for consumption by a person suffering from diabetes, overweight and/or obesity.
- the functional food may comprise 0.1 mg to 10 g of carnosine per 100 g of the food.
- the functional food may comprise about 0.1 , 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, or 10.0 g carnosine per 100 g of the food.
- the daily intake of carnosine may be about 0.5 to 20 g per day.
- the daily intake of carnosine may be about 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0, or 20 g per day.
- the functional food may comprise 0.01 mg to 10 g Salacia reticulata extract of the food.
- the functional food may comprise about 0.01 , 0.05, 0.1 , 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, or 10.0 g Salacia reticulata per 100 g of the food.
- the daily intake of Salacia reticulata extract may be about 0.01 to 20 g per day.
- the daily intake of Salacia reticulata extract may be about 0.01 , 0.05, 0.1 , 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, or 10.0 g, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0, or 20 g per day.
- the technical effect related to the use of carnosine and of an extract of Salacia reticulata in the production of a functional food composition relies in the improvement of the energy level of a subject as well as improving health and well-being of a subject in need thereof.
- the functional food according to the invention may allow the consumption of fast food or sweets without regret. Due to the supplementation of the fast food or sweets with carnosine and an extract of Salacia reticulata, the ingestion of these may not lead and/or even prevent with fast food and sweets associated negative effects to the consumer.
- Preparation comprising: 50 g orange juice, 30 g carrot juice, 5 g lemon juice, 1 - 1.9 g chia seeds, 12 g sweetener, 0.9 g ascorbic acid and 0.1 - 1 g Salacia reticulata extract.
- Preparation comprising: 50 g orange juice, 30 g carrot juice, 5 g lemon juice, 1 -1.9 g chia seeds, 12 g sweetener, 0.9 g ascorbic acid and 0.1 - 1 g Salacia reticulata extract.
- Preparation comprising: 50 g orange juice, 30 g carrot juice, 0 -4.9 g lemon juice, 2 g chia seeds, 12 g sweetener, 0.9 g ascorbic acid, 0.1 - 1 g Salacia reticulata extract and 0.1 mg to 5 g carnosine.
- Preparation comprising potatoes, sunflower oil, flavoring, table salt, yeast extract, paprika powder, sugar, onion powder, garlic powder, paprika extract, smoke flavoring, spice extracts, 0.1 to 1 wt.% Salacia reticulata extract and 0.1 to 5 wt.% carnosine.
- Example 7 Fruit juice products
- Examples of fruit juice products according to the invention are juices derived from citrus fruit like orange and grapefruit, tropical fruits, banana, peach, peer, strawberry or berry in which the wine extract and grape juice extract and optionally berry extract are dissolved or suspended.
- 0.1 to 5 wt.% carnosine and optionally 0.1 to 1 wt.% Salacia reticulata extract are added.
- the average serving size for the fruit juice products is 250 ml.
- dairy products according to the invention are milk, dairy spreads, cream cheese, milk type drinks and yoghurt, wherein the wine extract and grape juice extract and optionally berry extract are dissolved or suspended.
- wine extract and grape juice extract and optionally berry extract are dissolved or suspended.
- flavor or other additives may be added.
- composition for a yogurt type product is about 50 to 80 wt.% water, 0.1 to 15 wt.% hydrolyzed casein solids, 0 to 15 wt.% whey powder, 0 to 15 wt.% sugar (e.g. sucrose), 0.01 to 1 wt.% yogurt culture, 0 to 20 wt.% fruit, 0.05 to 5 wt.% vitamins and minerals, 0 to 2 wt.% flavor, 0 to 5 wt.% stabilizer (thickener or gelling agent).
- the yogurt type product comprises 0.1 to 5 wt.% carnosine and optionally 0.1 to 1 wt.% Salacia reticulata extract.
- An average serving size for a yogurt type product could be from 50 to 250 g, generally from 80 to 200 g.
- frozen confectionery product includes milk containing frozen confections such as ice-cream, frozen yoghurt, sherbet, sorbet, ice milk and frozen custard, water-ices, granitas and frozen fruit purees.
- the level of solids in the frozen confection e.g. sugar, fat, flavoring etc
- the level of solids in the frozen confection is more than 3 wt.%, more preferred from 10 to 70 wt.%, for example 40 to 70 wt.%.
- the frozen confectionery product comprises 0.1 to 5 wt.% carnosine and optionally 0.1 to 1 wt.% Salacia reticulata extract.
- Ice cream will typically comprise 0 to 20 wt.% of fat, 0.1 to 5 wt.% wine extract, 0.1 to 5 wt.% grape-juice, sweeteners, 0 to 10 wt.% of non-fat milk components and optional components such as emulsifiers, stabilizers, preservatives, flavoring ingredients, vitamins, minerals, etc., the balance being water.
- ice cream will be aerated e.g., to an overrun of 20 to 400 %, more specific 40 to 200 % and frozen to a temperature of from -2 to -200 °C, more specific -10 to -30 °C. Ice cream may comprise calcium at a level of about 0.1 wt%.
- the ice cream comprises and 0.1 to 5 wt.% carnosine and optionally 0.1 to 1 wt.% Satacia reticulata extract.
- the average serving size of a frozen confectionery product is 85g.
- Granola bars consists of a binder syrup which binds the granola and fruit ingredients into a solid bar.
- a binder syrup which binds the granola and fruit ingredients into a solid bar.
- E.g., nuts, pieces of chocolate, or a low moisture yoghurt filling can be added as well.
- the bar can be enrobed with a coating of e.g. chocolate or a low moisture yoghurt layer.
- the granola bar may comprise 0 to 40 wt.% granola base (oat flakes, wheat flakes, rice crispies); 0 to 60 wt.% binder syrup (corn syrup, sugar, salt, lecithin, vegetable oil), 0 to 40 wt.% fruit filling (low moisture jelly, dried fruits); moisture content is typically below 15%.
- the nutrition bar may comprise oat flakes/wheat flakes 0 to 25 wt.%, rice crispies 0 to 15 wt.%, corn syrup 0 to 50 wt.%, sugar 0 to 15 wt.%, lecithin 0 to 1 wt.%, salt 0 wt.1 %, vegetable oil 0 to 25 wt.%, dried fruits 0 to 20 wt.%, low moisture fruit jelly 0 to 20 wt.%, 0.1 to 5 wt.% carnosine, optionally 0.1 to 1 wt.% Satacia reticulata extract, stabilizers 0 to 2 wt.%. flavors 0 to 2 wt.%, and vitamins/minerals 0 to 5 wt.%. Stabilizers are often added to create a more solid fruit filling. The obtained products are ambient stable.
- the food product may be a spread, frozen confection, or sauce.
- a spread according to the invention comprises 30 to 90 wt.% vegetable oil and 0.1 to 5 wt. %carnosine, and optionally 0.1 to 1 wt.% Satacia reticulata extract.
- Other food product according to the invention can be prepared by the skilled person based on common general knowledge, using the wine extract and red grape juice extract and optionally berry extract as an ingredient in suitable amounts.
- Examples of such food products are baked goods, dairy type foods, snacks, etc.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Power Engineering (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a functional food composition comprising carnosine and a Salacia reticulata extract and to the use thereof for improving energy, health and well-being in a subject.
Description
FUNCTIONAL FOOD
Description
Field of the Invention
[0001] The present invention relates to a functional food for improving human nutrition and which contributes to human health in a sustainable manner.
Background Art
[0002] Obesity and diabetes are an increasing health problem in the population. The reasons often lie in poor diet and lifestyle.
[0003] As a countermeasure, appetite suppressants, diet products and nutritional supplements are mostly consumed, which, however, lead to the generally known "JoJo effect" after the end of the intake.
[0004] L-carnosine (0-alanyl-L-histidine, hereinafter referred to as carnosine) is a dipeptide discovered from the skeletal muscles in 1900's, and is present in high concentrations (1-20 mM) in the skeletal muscles of various vertebrates. Carnosine is a water-soluble antioxidant in the living body. Carnosine serves to stabilize the cell membrane by preventing the peroxidization of lipids in the membrane or by eliminating superoxide anions.
[0005] Carnosine is known not only as an antioxidant but as a neurotransmitter, an enzyme activity modulator, and a chelating agent for metal ions.
[0006] EP1285654A discloses a composition comprising carnosine, in which said composition comprises carnosine so that the amount of carnosine per ingestion is 0.7 pg/kg to 0.09 mg/kg, and which may take the form of a tablet, a capsule, powders, granules, a drink, bread, biscuit, cake and the like. The composition preferably has an effect of controlling the autonomic nervous system, and more specifically it has an effect of preventing, improving or alleviating disturbances in the autonomic nervous system and disease conditions resulting therefrom.
[0007] Herbal remedies are also used as a natural variant of food supplements in the form of extracts or crushed product. For example, in Ayurvedic medicine Salacia species are used for the treatment or alleviation of diabetes and obesity. Salacia is known to improve intestinal flora and is said to be effective against rheumatism, gonorrhea and skin diseases.
[0008] For example, W02008/142702A describes a synergistic bioactive Ayurvedic/functional food composition for the treatment of diabetes and related
disorders. The composition comprises extracts of at least two plants selected from a group consisting of Eugenia, Cinnamomum and Salacia obionga.
[0009] Medagama et al (Medagama Nutrition Journal 2015, 14(21 ):1 -8) provide an overview of the role of Salacia reticulata in the treatment of diabetes and obesity. Ofner et al (Cell Cycle 2013; 12:2, 346-352) describe complementary treatment of obesity and overweight with Salacia reticulata and vitamin D. Narda et al (Skin Pharmacol. Physiol. 2018, 31 :324-331) describe a new face cream containing carnosine that inhibits the formation of AGEs in human skin.
[0010] Currently, herbal remedies such as Salacia reticulata extracts are provided in the form of tablets or capsules that are taken as a supplement to conventional diet. [0011] There is still a need for new functional food which allow enjoyment without remorse and serve to rejuvenate and prolong human life without causing harmful side effects.
Summary of invention
[0012] The present invention is based on the task of functionalizing a conventional foodstuff by adding an extract of the plant Salacia reticulata / such a way that by consuming this foodstuff the extract can develop its comprehensive effect.
[0013] This task is solved by the independent claims. Thus, the present invention relates to a conventional food product which has been functionalized by adding an extract of the plant Salacia reticulata. By consuming this functionalized foodstuff, the extract of the plant Salacia reticulata contained in the foodstuff can develop its comprehensive effect.
Detailed description of the invention
[0014] 30% of our genes are responsible for signs of aging, the rest is due to the lifestyle. Aging is primarily related to changes in the proteins in the body. Proteins are the main building blocks of living organisms, so damaging them can have a dramatic impact on how the body functions and looks.
[0015] These protein changes result from
- free radical oxidation;
- glycation ("saccharification"); and
- carbonylation with loss of cell membranes, which leads to cell senescence and cell death.
[0016] All of these protein changes lead to the well-known signs of aging such as skin aging, chronic diseases such as stroke, cataracts, nerve degeneration (Alzheimer's disease), diabetes, muscle aging, reduced sexual and physical potency and much more.
[0017] Nutrition also has a major influence on skin aging. Skin aging is a complex, chronic process that takes place over several years and involves the interaction of external and intrinsic factors. Mechanisms such as oxidative stress caused by free radicals, inflammatory processes, cellular senescence and epigenetic changes are not mutually exclusive mechanisms that are part of skin aging.
[0018] Glycosylation, the non-enzymatic reaction between proteins and sugars that leads to the formation and subsequent accumulation of advanced glycosylation end products (AGEs), has been linked to microvascular and macrovascular complications in diabetes. AGEs have been found to be associated with extracellular matrix proteins such as collagen, vimentin, and elastin. AGE-modified collagen and elastin have been reported to have altered biomechanical properties that lead to loss of elasticity and increased stiffness, and thus to changes that promote the appearance of wrinkles.
[0019] Glycosylation also alters the interaction of collagen with cells, affecting their functions such as migration, differentiation, and proliferation. In recent years, a better understanding of the effects of AGEs on skin structure and functionality has brought the potential of anti-AGE agents into focus (Narda et aL, 2018).
[0020] In particular, l-carnosine has been associated with protection against glycosylation when taken orally.
[0021] Carnosine is a highly potent, multifunctional anti-aging protein that occurs 100% naturally in human long-lived cells such as nerve and muscle cells and decreases with age. Carnosine levels decline with age. Muscle levels decline 63% from age 10 to age 70, which may account for the normal age-related decline in muscle mass and function (Stuerenburg HJ et aL, Arch Gerontol Geriatr. 1999. 29: 107-113). Carnosine fights such age-inducing processes as oxidation, glycation, protein cross-linking, mitochondrial dysfunction, telomere shortening, 64 and transition metal accumulation. Therefore carnosine is may delay aging of subjects.
[0022] Carnosine was discovered at the beginning of the 20th century. Taken as a dietary supplement, carnosine could promote muscle growth and could reduce muscle damage caused by intensive training.
[0023] Carnosine restores normal cell cycle control. It keeps human proteins healthy and intact and ensures their timely renewal. Human cells have only a limited ability to divide over the course of life. Human fibroblasts (skin cells from which taut collagen fibers develop) divide 60-80 times when they are young and only 10-20 times when they get older, and may take on strikingly abnormal sizes and shapes in cell cultures (Sadowska-Bartosz I. and Bartosz G, Oxid Med Cell Longev. 2020 Sep 23;2020:6423783).
[0024] Mice fed with carnosine had a 20% longer lifespan, their fur became shiny again and they resembled young mice again, including in their more agile behavior (Yuneva M.O. et aL, Journal of Anti-Aging Medicine 1999 337-342; Boldyrev A.A. et al., Bioscience Reports volume 19, pages581-587 1999). Carnosin can thus show a biological rejuvenation. A special feature of carnosine is its ability to reverse the signs of aging.
[0025] In cell cultures supplemented with carnosine an increase in the life span could be demonstrated by up to 300%, which corresponds to 413 days (McFarland G.A. and Holliday R. Exp Gerontol. 1999 Jan;34(1):35-45).
[0026] The most important protein change and thus the cause of skin aging is glycation. Carnosine counteracts glycation ("saccharification of the cells") and thus leads to an increase in elasticity and firmness of the skin.
[0027] Glycation describes the binding of a protein molecule to glucose, whereupon advanced glycation end products (AGEs) are formed after several steps (Burcham PC, and Kuhan YT. Arch Biochem Biophys, 1997, 340(2):331-7).
[0028] Carnosine may delay age induced processes such as glycation. Carnosine is considered as the most effective glycation fighter. Glycation alters protein structure and decreases biological activity. Glycated proteins, which accumulate in affected tissue, are reliable markers of disease. Carnosine, which prevents glycation, may also play a role in the disposal of glycated protein (Aldini G. et al. , Biochem Biophys Res Commun. 2002 Nov 15;298(5):699-7062002, Yeargans G.S. and Seidler N.W.
Biochem Biophys Res Commun . 2003 Jan 3;300(1):75-80).
[0029] Carnosine increases the conversion of dangerous white fat into brown fat. This can reduce overall body fat content. Schaalan et al. suggest that carnosine may induce browning of adipose tissue through irisin stimulation, a phenomenon that could be
related to the antioxidant, anti-inflammatory, and anti-obesity effects of carnosine (Schaalan M.F. et al., J Cell Physiol . 2018 Jun;233(6):5044-5057).
[0030] Additionally, carnosine may ply a role in reverse aging. McFarland G.A. and Holliday R. have shown that a transfer of cells approaching senescence in normal medium to medium supplemented with carnosine rejuvenates the cells (McFarland
G.A. and Holliday R., Exp Cell Res . 1994 Jun;212(2):167-75).
[0031] Carnosine increased myocyte tension via calcium release from the ryanodine receptor calcium release channel in skinned myocardial fibers and increased openstate probability and dwell time of the isolated ryanodine receptor calcium release channel in lipid bilayers. In addition, we report that carnosine sensitizes the contractile proteins so calcium. These results suggest a novel role for carnosine as a modulator of intracellular calcium and contractility in cardiac tissue. Thus, carnosine may prevent heart attacks and stroke (Zaloga G.P. et al., Am J Physiol. 1997 Jan;272(1 Pt 2):H462- 8).
[0032] As stated above, carnosine exhibits anti-glycating and antioxidant activities, both of which are implicated in neuronal and endothelial cell damage during Alzheimer's disease. Carnosine may therefore be a useful therapeutic agent in the treatment of neurologic diseases such as Alzheimer(Preston J.E. et aL, Neurosci Lett. 1998 Feb 13;242(2): 105-8, Aksenova MV, et aL, J Neurosci Res. 1999; 58(2):308-17, Cherny RA, et aL, J Biol Chem . 1999;274:23223-8).
[0033] Atherosclerosis, a chronic inflammatory disorder of medium and large arteries and an underlying cause of cardiovascular disease (CVD), is responsible for a third of all global deaths. Carnosine may represent a promising agent in the prevention and treatment of atherosclerosis (Moss J.W.E. et aL, Biochim Biophys Acta Mol Basis Dis. 2018 May; 1864(5 Pt A): 1562-1572).
[0034] The anti-ageing effect of carnosine had been demonstrated in many studies in vivo and in vitro. More recently, there were some studies verifying the effect of carnosine on preventing cataract development. The effect of carnosine on delaying the cataract formation may be through anti-glycation of protein, antioxidative impairment, protection protein against cross-links and DNA damage. Carnosine may provide a new therapy for preventing eye diseases such as glaucoma or cataracts (Guo Y. and Yan
H. Yan ke xue bao (2016), 01 Jun 2006, 22(2):85-88).
[0035] These AGEs interact with neighboring proteins, leading to protein alteration and accelerated aging such as: skin flaccidity; stiffening of the arteries with the development of cardiovascular diseases; damage to the nerves in the brain; cataract; kidney failure and a lot more.
[0036] The slower a species ages, the slower its collagen stiffens due to AGEs and the skin stays taut.
[0037] A drug that could slow or reverse AGEs accumulation would thus benefit people with a wide range of diseases and conditions. It could potentially alleviate or even cure problems as wide-ranging as the rise in blood pressure with age, the kidney, nerve and eye complications of diabetes, and several forms of heart failure. The therapeutic potential of carnosine has already been demonstrated in diabetics with kidney problems (Sourris K.C. et al, Am J Nephrol (2009) 30 (4): 323-335). Janssen B. et al. describe that carnosine exerts a protective effect against the adverse effects of high glucose levels on renal cells (Janssen B. et aL, Diabetes (2005) Aug;54(8):2320- 7).
[0038] Since AGEs have been identified as potential factors for aging, the antiglycation properties of carnosine are of utmost importance for any anti-aging project. [0039] Therefore, carnosine may be the most effective natural glycation inhibitor. [0040] Another protein change results from oxidation/oxidative stress by free radicals. Carnosine is far superior to the previous antioxidants such as vitamins C and E, or selenium. These have not been proven as effective as previously assumed. Carnosine is not only effective in prevention, but also acts actively after free radicals have been formed. The formation of dangerous secondary products that play a role in atherosclerosis, joint inflammation, cataracts, etc. and general aging may be prevented or reduced by carnosine (Schmidt AM et aL, Circ Res 1999; 84(5):489-97).
[0041] Carnosine has also been reported to delay the replicative senescence. Shao L. et al. suggest that the reduction in telomere shortening rate and damages in telomeric DNA made an important contribution to the life-extension effect of carnosine (Shao L. et aL, Biochem Biophys Res Commun 2004 324(2):931 -6).
[0042] Oxidative stress may cause chromosome breaks and may lead to clumping upon coming of age. A fascinating experiment shows the paradoxical effects of antioxidants on oxidatively damaged chromosomes. The oxygen partial pressure in the blood of hamsters was increased and then the ability of individual antioxidants such as vitamin C and E etc. to protect the chromosomes in the hamster ovaries from oxidative damage was investigated. Surprisingly, some of the antioxidants tested acted pro- oxidatively and worsened the damage.
[0043] The positive effects of carnosine relating to anti-aging effect through increased elasticity and firmness of the skin; extension of the lifespan of mice with accelerated senescence (aging) by 20%, in cell cultures by 300%; dramatically improves the behavior and appearance of old mice; rejuvenates aged (old) human cells in culture; restores the youthful appearance of cells approaching senescence; most effective, natural glycation fighter, thereby counteracting the saccharification of cells (collagen fibers remain firm, protection against cardiovascular diseases, etc.); protects in a natural way against the toxicity of copper-zinc in the brain and thus against the development of memory disorders and Alzheimer's; increase in physical and mental potency; protects proteins from changes and toxicity of AGEs and thus from diabetes and its complications; and positive effects on energy, health and well-being.
[0044] After just 2 months of daily intake, visible and noticeable results are possible, such as an improvement in the complexion, an increase in vitality and well-being. Together with a change in lifestyle sustainable weight loss may be achieved.
[0045] High doses of carnosine are necessary for a visible and therapeutic effect, as the body naturally breaks it down enzymatically. The absorption from food is 30% on average, is absorbed in the small intestine and from there transported to the muscles, skin, brain and other organs. With increasing age, the carnosine level in the body decreases.
[0046] Carnosine is 100% natural, gluten, soy and lactose free, and even in high doses completely safe. So far, no side effects or interactions with other drugs are known.
[0047] According to the invention, a functional food is provided which allows "enjoyment without regrets". The intake of the functional food may improve health and possible save on prescription of medicines. The present invention relates to a highly potent, water-soluble anti-AGE active ingredient in food for general consumption, as a so-called functional food or luxury food ("enjoyment without regrets") such as alcohol- free spirits, confectionery, snacks or fruit/vegetable products. The functional food may be ideal for healthy people who want to age youthfully, but also as an auxiliary food for people suffering from obesity, diabetes or other chronic diseases.
[0048] In a further embodiment of the invention, the functional food may comprise a Salacia reticulata extract.
[0049] The genus Salacia consists of about 120 species, such as Salacia reticulata, Salacia oblonga, Salacia chinensis or Salacia prinoides, and is widely distributed in Sri Lanka, India, China, Vietnam, Indonesia and other Asian countries.
[0050] Numerous compounds with blood sugar-lowering effects have already been isolated from Salacia species, such as triterpenes and sitosterol from roots and barks. In the roots of Salacia reticulata, mangiferin, cotalanol and salacinol were found, which are mainly thought to be responsible for the blood sugar lowering effect. In addition, a thiocyclitol compound has been isolated from this plant with hypoglycemic properties, and furthermore, several other constituents such as dulcitol, tannins, cotalagenin, maytenfolic acid, and soiguesterin (Medagama AB, Medagama Nutrition Journal (2015) 14:21 ;1-8).
[0051] Studies in animal models and humans have shown that Salacia reticulata improves glucose metabolism, mainly by inhibiting alpha-glucosidase, thereby delaying the cleavage of poly- and oligosaccharides in the small intestine into easily absorbed monosaccharides and consequently their absorption. Extracts of Salacia reticulata thus attenuate postprandial hyperglycemia and hypersinsulinemia (Medagama AB, 2015). [0052] Salacia also improves insulin resistance by suppressing pancreatic lipase activity, which is a crucial enzyme in the pancreas for the digestion of dietary fat. Extracts of Salacia reticulata ihus attenuate postprandial hyperlipidemia. Further
studies have shown increased secretion of adiponectin, which further improves insulin resistance (Medagama AB, 2015).
[0053] Diet and eating behavior play a very important role in the development of obesity. The main problem is the excessive energy intake over a longer period of time. The problem is that it is usually not just an isolated "bad" habit, but eating too often, too much, too fast, too fat, too sweet and too salty in equal measure. One can summarize all the "dietary sins" mentioned with the term "fast food".
[0054] The high content of polyphenols (24%) such as mangiferin, catechins and condensed tannins in the extract of Salacia reticulata, could be responsible for the reduction of body weight when taken in higher doses.
[0055] Carnosine is a dipeptide synthesized in the body from p-alanine and L- histidine. It is found in high concentrations in the brain, muscle, and gastrointestinal tissues of humans and is present in all vertebrates. Carnosine has a number of beneficial antioxidant properties. For example, carnosine scavenges reactive oxygen species (ROS) as well as alpha-beta unsaturated aldehydes created by peroxidation of fatty acid cell membranes during oxidative stress. Carnosine can oppose glycation, and it can chelate divalent metal ions. Carnosine alleviates diabetic nephropathy by protecting podocyte and mesangial cells, and can slow down aging. Its component, the amino acid beta-alanine, is particularly interesting as a dietary supplement for athletes because it increases muscle carnosine, and improves effectiveness of exercise and stimulation and contraction in muscles. Carnosine is widely used among athletes in the form of supplements, but rarely in the population of cardiovascular or diabetic patients. Much less is known, if any, about its potential use in enriched food.
[0056] As an anti-AGE active ingredient, carnosine increases and tightens the elasticity of the skin. Carnosine is able to significantly reduce the external signs of aging by extending the lifespan (in cell cultures up to 300%, equivalent to 413 days) and by rejuvenating old, senescent cells. As an antioxidant, it leads to slow aging due to its pronounced cell protection and thus has a cell rejuvenating effect without the risk of side effects.
[0057] In addition, carnosine is able to prevent intramuscular hyperacidity by reducing the accumulation of lactate, regulate the energy metabolism of muscles and thus improve physical performance. This in turn has positive effects on the overall physical
fitness which is reflected in higher vital energy, vitality and an improvement in the overall health of the person.
[0058] In addition, anti-inflammatory and anti-aggregation properties expand the therapeutic range of carnosine. This therapeutic potential has already seen initial success in the treatment of type 2 diabetes mellitus, Alzheimer's disease and cardiovascular disease.
[0059] As used herein, the term "plant extract" refers to a substance obtained from plant material. Plant extracts may be prepared by treating any plant material with a suitable extractant to provide an extract containing at least some components of the plant material from the plant material in aqueous solution or suspension. The plant material treated with an extractant to provide a plant extract may be any part of or derived from a plant, for example, the bark, roots, leaves, flowers, seeds or fruits of the plant.
[0060] Methods for preparing plant extracts are well known to the skilled person. For example, the plant extracts may be obtained by decoction, digestion, percolation, soxlethtation, maceration, or any other suitable extraction method.
[0061] In the preparation of plant extract, the plant components extracted from the plant material will be at least partially soluble or suspendable in an extractant, preferably an organic solvent or water. After treatment of the plant material with the extractant, the insoluble plant material may remain in the extractant, or the insoluble plant material may be separated from the extractant. The insoluble plant material may be separated from the extractant by any suitable method, for example, decantation, filtration, or centrifugation.
[0062] For example, the insoluble plant material is separated from the extractant, and the plant extract contains no insoluble components.
[0063] For example, the plant extract is in aqueous solution or in a form where the extractant has been sufficiently removed to provide a dry or non-aqueous extract. Preferably, the plant extract Salacia reticulata is obtained from the roots and/or stem bark of a plant of the genus Salacia reticulata.
[0064] According to the present invention the Salacia reticulata extract is directly processed or incorporated into a food product to thereby provide a functional food. [0065] Other active ingredients can be added to the functional food, such as cinnamon, vitamins and the like.
[0066] The present invention relates to food products made by combining various dairy (substitute), chocolate, sugar, dough, cereal, meat, and fish-based products, as well as fruits and vegetables. Functional foods may also include beverages. The functional foods may contain other ingredients such as flavors, sweeteners, flow regulators, and anti-caking agents.
[0067] For example, functional foods are selected from the group consisting of yogurts, yogurt substitutes, dips, spreads, pastes, snacks, ice cream, candies, cookies, cakes, cereal bars, fruit bars, smoothies, and the like.
[0068] The term "snacks", as used herein, is understood to mean food products produced as a composition of various processed and unprocessed foods/products. Such snacks can be produced by conventional processes known to the skilled person. The functional food according to the invention is suitable as a food of general consumption by a healthy person, or as a food for consumption by a person suffering from diabetes, overweight and/or obesity.
[0069] The functional food may comprise 0.1 mg to 10 g of carnosine per 100 g of the food. The functional food may comprise about 0.1 , 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, or 10.0 g carnosine per 100 g of the food.
[0070] The daily intake of carnosine may be about 0.5 to 20 g per day. The daily intake of carnosine may be about 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0, or 20 g per day.
[0071] The functional food may comprise 0.01 mg to 10 g Salacia reticulata extract of the food. The functional food may comprise about 0.01 , 0.05, 0.1 , 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, or 10.0 g Salacia reticulata per 100 g of the food.
[0072] The daily intake of Salacia reticulata extract may be about 0.01 to 20 g per day. The daily intake of Salacia reticulata extract may be about 0.01 , 0.05, 0.1 , 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, or 10.0 g, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0, or 20 g per day.
[0073] The technical effect related to the use of carnosine and of an extract of Salacia reticulata in the production of a functional food composition relies in the improvement of the energy level of a subject as well as improving health and well-being of a subject in need thereof. Specifically, the functional food according to the invention may allow the consumption of fast food or sweets without regret. Due to the supplementation of the fast food or sweets with carnosine and an extract of Salacia reticulata, the
ingestion of these may not lead and/or even prevent with fast food and sweets associated negative effects to the consumer.
[0074] The examples described herein are illustrative of the present invention and not intended to be limitations thereof.
Examples
[0075] The Examples which follow are set forth to aid in the understanding of the invention but are not intended to, and should not be construed to limit the scope of the invention in any way. The Examples do not include detailed descriptions of conventional methods. Such methods are well known to those of ordinary skill in the art.
Example 1 - Preparation of an ice cream
[0076] Preparation comprehensive: 20 g powdered sugar, 15 g whole milk, 15 g mascarpone, 15 g orange juice, 15 g lemon juice, 15 g strawberries, 1 egg yolk, 1 - 1.9 g Cointreau, 0.1 - 1 g Salacia reticulata extract.
Example 2 - Preparation of a muesli bar
[0077] Preparation comprehensive: 30 g rolled oats, 18 g rice syrup, 12 g dates, 10 g agave syrup, 9 g coconut chips, 8 g cranberries, 6 g sunflower oil 4 g raisins, 1 - 1.9 g quinoa, 1 g salt and 0.1 - 1 g Salacia reticulata extract.
Example 3 - Preparation of a smoothie
[0078] Preparation comprising: 50 g orange juice, 30 g carrot juice, 5 g lemon juice, 1 - 1.9 g chia seeds, 12 g sweetener, 0.9 g ascorbic acid and 0.1 - 1 g Salacia reticulata extract.
Example 4 - Preparation of a smoothie
[0079] Preparation comprising: 50 g orange juice, 30 g carrot juice, 5 g lemon juice, 1 -1.9 g chia seeds, 12 g sweetener, 0.9 g ascorbic acid and 0.1 - 1 g Salacia reticulata extract.
Example 5 - Preparation of a smoothie
[0080] Preparation comprising: 50 g orange juice, 30 g carrot juice, 0 -4.9 g lemon juice, 2 g chia seeds, 12 g sweetener, 0.9 g ascorbic acid, 0.1 - 1 g Salacia reticulata extract and 0.1 mg to 5 g carnosine.
Example 6 - Preparation of a snack (potato chips)
[0081] Preparation comprising potatoes, sunflower oil, flavoring, table salt, yeast extract, paprika powder, sugar, onion powder, garlic powder, paprika extract, smoke
flavoring, spice extracts, 0.1 to 1 wt.% Salacia reticulata extract and 0.1 to 5 wt.% carnosine.
Example 7 - Fruit juice products
[0082] Examples of fruit juice products according to the invention are juices derived from citrus fruit like orange and grapefruit, tropical fruits, banana, peach, peer, strawberry or berry in which the wine extract and grape juice extract and optionally berry extract are dissolved or suspended. To the composition 0.1 to 5 wt.% carnosine and optionally 0.1 to 1 wt.% Salacia reticulata extract are added. The average serving size for the fruit juice products is 250 ml.
Example 8 - Dairy type products
[0083] Examples of dairy products according to the invention are milk, dairy spreads, cream cheese, milk type drinks and yoghurt, wherein the wine extract and grape juice extract and optionally berry extract are dissolved or suspended. Optionally flavor or other additives may be added.
[0084] An example of a composition for a yogurt type product is about 50 to 80 wt.% water, 0.1 to 15 wt.% hydrolyzed casein solids, 0 to 15 wt.% whey powder, 0 to 15 wt.% sugar (e.g. sucrose), 0.01 to 1 wt.% yogurt culture, 0 to 20 wt.% fruit, 0.05 to 5 wt.% vitamins and minerals, 0 to 2 wt.% flavor, 0 to 5 wt.% stabilizer (thickener or gelling agent). The yogurt type product comprises 0.1 to 5 wt.% carnosine and optionally 0.1 to 1 wt.% Salacia reticulata extract.
[0085] An average serving size for a yogurt type product could be from 50 to 250 g, generally from 80 to 200 g.
Example 9 - Frozen Confectionery Products
[0086] For the purpose of the invention the term frozen confectionery product includes milk containing frozen confections such as ice-cream, frozen yoghurt, sherbet, sorbet, ice milk and frozen custard, water-ices, granitas and frozen fruit purees.
[0087] Preferably the level of solids in the frozen confection e.g. sugar, fat, flavoring etc) is more than 3 wt.%, more preferred from 10 to 70 wt.%, for example 40 to 70 wt.%. The frozen confectionery product comprises 0.1 to 5 wt.% carnosine and optionally 0.1 to 1 wt.% Salacia reticulata extract.
[0088] Ice cream will typically comprise 0 to 20 wt.% of fat, 0.1 to 5 wt.% wine extract, 0.1 to 5 wt.% grape-juice, sweeteners, 0 to 10 wt.% of non-fat milk components and optional components such as emulsifiers, stabilizers, preservatives, flavoring
ingredients, vitamins, minerals, etc., the balance being water. Typically ice cream will be aerated e.g., to an overrun of 20 to 400 %, more specific 40 to 200 % and frozen to a temperature of from -2 to -200 °C, more specific -10 to -30 °C. Ice cream may comprise calcium at a level of about 0.1 wt%. The ice cream comprises and 0.1 to 5 wt.% carnosine and optionally 0.1 to 1 wt.% Satacia reticulata extract.
[0089] The average serving size of a frozen confectionery product is 85g.
Example 10 - Nutrition bare
[0090] As example a composition of a granola bar is given. Granola bars consists of a binder syrup which binds the granola and fruit ingredients into a solid bar. E.g., nuts, pieces of chocolate, or a low moisture yoghurt filling can be added as well. The bar can be enrobed with a coating of e.g. chocolate or a low moisture yoghurt layer.
[0091] For example, the granola bar may comprise 0 to 40 wt.% granola base (oat flakes, wheat flakes, rice crispies); 0 to 60 wt.% binder syrup (corn syrup, sugar, salt, lecithin, vegetable oil), 0 to 40 wt.% fruit filling (low moisture jelly, dried fruits); moisture content is typically below 15%.
[0092] The nutrition bar may comprise oat flakes/wheat flakes 0 to 25 wt.%, rice crispies 0 to 15 wt.%, corn syrup 0 to 50 wt.%, sugar 0 to 15 wt.%, lecithin 0 to 1 wt.%, salt 0 wt.1 %, vegetable oil 0 to 25 wt.%, dried fruits 0 to 20 wt.%, low moisture fruit jelly 0 to 20 wt.%, 0.1 to 5 wt.% carnosine, optionally 0.1 to 1 wt.% Satacia reticulata extract, stabilizers 0 to 2 wt.%. flavors 0 to 2 wt.%, and vitamins/minerals 0 to 5 wt.%. Stabilizers are often added to create a more solid fruit filling. The obtained products are ambient stable.
Example 11 - Fruit spreads
[0093] The food product may be a spread, frozen confection, or sauce. A spread according to the invention comprises 30 to 90 wt.% vegetable oil and 0.1 to 5 wt. %carnosine, and optionally 0.1 to 1 wt.% Satacia reticulata extract.
[0094] Other food product according to the invention can be prepared by the skilled person based on common general knowledge, using the wine extract and red grape juice extract and optionally berry extract as an ingredient in suitable amounts.
Examples of such food products are baked goods, dairy type foods, snacks, etc.
Claims
1. A functional food composition comprising carnosine and a Salacia reticulata extract.
2. The functional food composition according to claim 1 , wherein carnosine has been synthetically produced.
3. The functional food product according to claim 1 or 2, wherein the functional food composition comprises 0.1 mg to 10 g of carnosine per 100 g of the food.
4. The functional food composition of any one of claims 1 to 3, wherein the Salacia reticulata extract is obtained from roots and/or stem bark of Salacia reticulata.
5. The functional food composition of any one of claims 1 to 4, wherein the Salacia reticulata extract contains saponins and vitamin D.
6. The functional food composition of any one of claims 1 to 5, wherein the functional food composition comprises 0.01 mg to 10 g Salacia reticulata extract per 100 g of the food product.
7. The functional food composition of any one of claims 1 to 6, wherein the functional food composition is composed of diverse processed and non-processed food products.
8. The functional food composition of any one of claims 1 to 7, wherein the food product is selected from the group consisting of yogurts, dips, spreads, pastes, snacks, ice cream, candies, cookies, cakes, cereal bars, fruit bars, smoothies.
9. The functional food composition of any one of claims 1 to 8 for use in improving energy, health and well-being of a subject.
10. Use of carnosine and of an extract of in Salacia reticulata in the production of a functional food composition to improve energy, health and well-being of a subject which is to be ingested and which comprises an amount of about 0.1 mg to 10 g of carnosine per 100 g of the food product and 0.01 mg to 10 g Salacia reticulata extract per 100 g of the food product.
11. The use according to claim 9, wherein the functional food composition contributes to the treatment and/or prevention of obesity or diabetes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATGM50138/2022U AT17991U1 (en) | 2022-09-08 | 2022-09-08 | FUNCTIONAL FOOD |
ATGM50138/2022 | 2022-09-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024052120A1 true WO2024052120A1 (en) | 2024-03-14 |
Family
ID=87973353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/073045 WO2024052120A1 (en) | 2022-09-08 | 2023-08-22 | Functional food |
Country Status (2)
Country | Link |
---|---|
AT (1) | AT17991U1 (en) |
WO (1) | WO2024052120A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1285654A1 (en) | 2001-03-16 | 2003-02-26 | Suntory Limited | Autonomic controlling agents and health drinks and foods |
WO2008142702A1 (en) | 2007-05-23 | 2008-11-27 | Avesthagen Limited | A synergistic ayurvedic / functional food bioactive composition [cincata] |
US20140017337A1 (en) * | 2012-07-11 | 2014-01-16 | Paul Amoruso | Therapeutic methods |
US20190192600A1 (en) * | 2016-09-02 | 2019-06-27 | Fujifilm Corporation | Feed for domestic animals or supplement for domestic animals, growth-promoting agent for bacterium of genus lactobacillus, and method for promoting growth of bacterium of genus lactobacillus |
JP2019147820A (en) * | 2008-09-30 | 2019-09-05 | 小林製薬株式会社 | Metabolism activator |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000086653A (en) * | 1998-09-14 | 2000-03-28 | Ranka Aayurubeedick Haabu Yakuhin Kk | Disaccharide hydrolase inhibitor |
-
2022
- 2022-09-08 AT ATGM50138/2022U patent/AT17991U1/en unknown
-
2023
- 2023-08-22 WO PCT/EP2023/073045 patent/WO2024052120A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1285654A1 (en) | 2001-03-16 | 2003-02-26 | Suntory Limited | Autonomic controlling agents and health drinks and foods |
WO2008142702A1 (en) | 2007-05-23 | 2008-11-27 | Avesthagen Limited | A synergistic ayurvedic / functional food bioactive composition [cincata] |
JP2019147820A (en) * | 2008-09-30 | 2019-09-05 | 小林製薬株式会社 | Metabolism activator |
US20140017337A1 (en) * | 2012-07-11 | 2014-01-16 | Paul Amoruso | Therapeutic methods |
US20190192600A1 (en) * | 2016-09-02 | 2019-06-27 | Fujifilm Corporation | Feed for domestic animals or supplement for domestic animals, growth-promoting agent for bacterium of genus lactobacillus, and method for promoting growth of bacterium of genus lactobacillus |
Non-Patent Citations (25)
Title |
---|
AKSENOVA MV ET AL., J NEUROSCI RES., vol. 58, no. 2, 1999, pages 308 - 17 |
ALDINI G. ET AL., BIOCHEM BIOPHYS RES COMMUN., vol. 298, no. 5, 15 November 2002 (2002-11-15), pages 699 - 7062002 |
BIOGROUP: "Glicasin", 28 June 2021 (2021-06-28), XP002810636, Retrieved from the Internet <URL:https://www.biogroup.it/shop/phytotherapy/glicasin/?lang=en> [retrieved on 20231205] * |
BOLDYREV A.A. ET AL., BIOSCIENCE REPORTS, vol. 19, 1999, pages 581 - 587 |
BURCHAM PCKUHAN YT, ARCH BIOCHEM BIOPHYS, vol. 340, no. 2, 1997, pages 331 - 7 |
CHERNY RA ET AL., J BIOL CHEM, vol. 274, 1999, pages 23223 - 8 |
D. NARDA ET AL., SKIN PHARMACOL. PHYSIOL., vol. 31, 2018, pages 324 - 331 |
GUO Y.YAN H, YAN KE XUE BAO, vol. 22, no. 2, 1 June 2006 (2006-06-01), pages 85 - 88 |
JANSSEN B ET AL., DIABETES, vol. 54, no. 8, 2005, pages 2320 - 7 |
MCFARLAND G.A.HOLLIDAY R., EXP CELL RES, vol. 212, no. 2, June 1994 (1994-06-01), pages 167 - 75 |
MCFARLAND G.AHOLLIDAY R, EXP GERONTOL, vol. 34, no. 1, January 1999 (1999-01-01), pages 35 - 45 |
MEDAGAMA ET AL., MEDAGAMA NUTRITION JOURNAL, vol. 14, no. 21, 2015, pages 1 - 8 |
MICHAEL OFNER ET AL: "Complementary treatment of obesity and overweight with salacia reticulata and vitamin d", INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH, vol. 83, no. 4, 1 January 2013 (2013-01-01), pages 216 - 223, XP093079869 * |
MOSS J.W.E. ET AL., BIOCHIM BIOPHYS ACTA MOL BASIS DIS., vol. 1864, May 2018 (2018-05-01), pages 1562 - 1572 |
OFNER ET AL., CELL CYCLE, vol. 12, no. 2, 2013, pages 346 - 352 |
PRESTON J.E. ET AL., NEUROSCI LETT., vol. 242, no. 2, 13 February 1998 (1998-02-13), pages 105 - 8 |
SADOWSKA-BARTOSZ IBARTOSZ G, OXID MED CELL LONGEV, 23 September 2020 (2020-09-23) |
SCHAALAN M.F. ET AL., J CELL PHYSIOL, vol. 233, no. 6, June 2018 (2018-06-01), pages 5044 - 5057 |
SCHMIDT AM ET AL., CIRC RES, vol. 84, no. 5, 1999, pages 489 - 97 |
SHAO L. ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 324, no. 2, 2004, pages 931 - 6 |
SOURRIS K.C. ET AL., AM J NEPHROL, vol. 30, no. 4, 2009, pages 323 - 335 |
STUERENBURG HJ ET AL., ARCH GERONTOL GERIATR, vol. 29, 1999, pages 107 - 113 |
YEARGANS G.S.SEIDLER N.W., BIOCHEM BIOPHYS RES COMMUN, vol. 300, no. 1, 3 January 2003 (2003-01-03), pages 75 - 80 |
YUNEVA M.O. ET AL., JOURNAL OF ANTI-AGING MEDICINE, 1999, pages 337 - 342 |
ZALOGA G.P. ET AL., AM J PHYSIOL., vol. 272, January 1997 (1997-01-01) |
Also Published As
Publication number | Publication date |
---|---|
AT17991U1 (en) | 2023-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Badrie | Nutrient profile, bioactive components, and functional properties of okra (Abelmoschus esculentus (L.) Moench) | |
KR100856241B1 (en) | A diet food composition using an agar | |
JPH11187843A (en) | Food and beverage composition for improving obesity and food and beverage containing the same | |
CN112042862A (en) | Weight-losing meal-replacing food and application | |
US20200155589A1 (en) | Composition For Enchanced Recovery After Surgery (ERAS) | |
KR20160144791A (en) | Composition for relieving menopausal symptom | |
KR100549193B1 (en) | Foods comprising ginseng and powders or extracts of plants comprising polyphenol or bioflavonoid for suppressing the fatness | |
RU2411756C2 (en) | Method for production of cereal product for instant kasha and instant kasha production method | |
JP6406730B1 (en) | Composition, body weight or body fat increase inhibitor, and body weight or body fat decrease promoter | |
KR100503208B1 (en) | Diet-food composition | |
KR102487651B1 (en) | A composition for preventing, improving or treating sarcopenia comprising extracts of wheat sprout | |
WO2024052120A1 (en) | Functional food | |
JP2008050301A (en) | Pancreatic lipase inhibitor | |
Saenz | Opuntia spp. Bioactive compounds in foods: a plus for health | |
JP4623999B2 (en) | Aldose reductase activity inhibitor, preventive / therapeutic agent for diabetic complications, and food and drink for the prevention / treatment of diabetic complications | |
KR101261146B1 (en) | Functional Food Composition having obesity control effect and the preparation method thereof | |
KR101344564B1 (en) | Composition comprising extract of hot peppers and Chinese peppers for preventing or treating of obesity or hyperlipidemia | |
CN110856501A (en) | Enzyme jade cake and preparation method thereof | |
CN110876476A (en) | Sweet osmanthus flower-lotus root starch instant soup capable of soothing nerves, strengthening brain, clearing heat and beautifying face and preparation method thereof | |
KR102649974B1 (en) | Composition for improving muscle function comprising ginsenoside Rf, ginsenoside composition comprising gincenoside Rf, or mixture thereof as an effective component | |
Rajput et al. | Chia Seeds: Composition, health benefits, and potential applications | |
JP7529207B2 (en) | Antidepressant composition containing buckwheat-derived ingredients | |
KR102478971B1 (en) | Composition for bowel movement promotion or diet | |
KR100777351B1 (en) | Health food comprising extracts of germinated Rhynchosia Volubilis as active ingredients for prevention or treatment of osteoporosis | |
KR102485676B1 (en) | A composition for improving, preventing and treating of obesity comprising Ulva pertusa Kjellman extracts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23758639 Country of ref document: EP Kind code of ref document: A1 |